Sickle cell disease trials recruiting in District of Columbia

All Sickle cell disease trials nationally

Cities in District of Columbia

Recruiting trials in District of Columbia

• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
  NCT06612268 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
  NCT06439082 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
  NCT04398628 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · District of Columbia: Washington D.C.
• Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease
  NCT06770010 · Phase: Not applicable (e.g. observational or device study) · Ages: 7 Years to 16 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
  NCT06941389 · Phase: Not specified · Ages: 3 Years to 20 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Cooperative Assessment of Late Effects for SCD Curative Therapies
  NCT05153967 · Phase: Not specified · Ages: 4 Years to 65 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
  NCT05099874 · Phase: Not applicable (e.g. observational or device study) · Ages: 8 Years to 16 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
  NCT06635902 · Phase: Phase 2 · Ages: 4 Years to 21 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
  NCT03587272 · Phase: Phase 2 · Ages: 2 Years to 25 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Natural History of Sickle Cell Disease
  NCT00081523 · Phase: Not specified · Ages: 2 Years to 90 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
  NCT04657822 · Phase: Phase 4 · Ages: 6 Months to 100 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
  NCT06358638 · Phase: Phase 2 · Ages: 2 Years to 25 Years · Sex: All (male and female) · District of Columbia: Washington D.C.